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Abstract
A series of fatty alkyl trifluoromethyl ketones and methyl fluorophosphonates have been prepared and tested as inhibitors
and inactivators of human groups IV and VI phospholipases A2 (cPLA2 and iPLA2). Compounds were analyzed with
phospholipid vesicle-, detergent-phospholipid mixed-micelle-, and natural membrane-based assays, and, with few exceptions,
the relative inhibitor potencies measured with the three assays were similar. Ph(CH2)4COCF3 and Ph(CH2)4PO(OMe)F
emerged as a potent inhibitor and inactivator, respectively, of iPLA2, and both are poorly effective against cPLA2. Of all 13
fatty alkyl trifluoromethyl ketones tested, the trifluoromethyl ketone analog of arachidonic acid is the most potent cPLA2
inhibitor, and structurally similar compounds including the trifluoromethyl ketone analog of docosahexenoic acid are much
poorer cPLA2 inhibitors. Inactivation of cPLA2 by fatty alkyl fluoromethylphosphonates is greatly promoted by binding of
enzyme to the interface. The use of both vesicles and mixed micelles to assay phospholipase A2 inhibitors and inactivators
present at low mol fraction in the interface provides reliable rank order potencies of a series of compounds that correlate with
their behavior in a natural membrane assay. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Phospholipases A2 (PLA2) are thought to liberate
arachidonic acid (20:4) from the sn-2 position of
cellular membrane phospholipids for the biosynthesis
of eicosanoids and possibly for other purposes [1^5].
There is considerable interest in PLA2 inhibitors as
such components should have antiin£ammatory
properties [6^8]. Compared to enzymes that work
in the homogeneous aqueous phase, inhibition of
PLA2s is more di⁄cult to study because these en-
zymes necessarily work at the lipid-water interface.
Many previously reported reversible inhibitors of
PLA2 have been shown to operate by a non-speci¢c
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mechanism in which an inhibitor occupies a signi¢-
cant fraction of the membrane surface and causes
desorption of the enzyme into the aqueous phase
[9]. Obviously, one desires highly speci¢c and potent
competitive inhibitors of PLA2 which function by
binding to the enzyme’s active site.
Many competitive inhibitors of PLA2s have been
studied with phospholipid vesicles [10] and with
phospholipid-detergent mixed micelles [11,12]. It
thus becomes important to determine if both systems
give reliable inhibition information. By reliable, it is
meant that the relative potencies of a series of inhib-
itors determined with PLA2 assays involving arti¢-
cial interfaces are the same as those determined with
natural membrane assays.
Ten groups of PLA2s have been identi¢ed based
on amino acid sequences [13,14]. The present study is
focused on two intracellular PLA2s: human group
IV PLA2, also called cytosolic PLA2 (cPLA2), and
the murine group VI PLA2, also called calcium-in-
dependent phospholipase A2 (iPLA2). Activation of
cPLA2 in cells by pro-in£ammatory agonists leads to
its calcium-dependent translocation from the cytosol
to intracellular membranes and release of arachi-
donic acid for eicosanoid biosynthesis [2]. The func-
tion of iPLA2 is probably as a constitutively active
enzyme that removes sn-2 acyl chains for phospho-
lipid remodeling [15,16].
The fatty acid analog 20:4-COCF3 (also known as
AACOCF3, Fig. 1) has been shown to be a tight
binding, reversible inhibitor of cPLA2 [17] and iPLA2
[18], presumably by forming a stable hemiketal with
the active site serine residues of these enzymes. An-
other fatty acid analog 20:4-PO(OMe)F (also known
as MAFP, Fig. 1) has been shown to irreversibly
inactivate cPLA2 [19] and iPLA2 [20], possibly by
phosphorylation of serine. 20:4-COCF3 and 20:4-
PO(OMe)F do not inhibit secreted PLA2s. In this
study we have prepared a series of analogs of 20:4-
COCF3 and 20:4-PO(OMe)F and have measured
their potencies against cPLA2 and iPLA2 using
vesicle, mixed-micelle, and natural membrane assays.
As noted above, comparison of these structure-activ-
ity studies using multiple assays is important given
the fact that multiple types of aggregated substrates
for PLA2 continue to be used by workers in the ¢eld.
In addition, we sought to develop analogs of 20:4-
COCF3 and 20:4-PO(OMe)F that can distinguish
between cPLA2 and iPLA2.
2. Materials and methods
2.1. Materials
1-Palmitoyl-2-[1-14C]arachidonyl-sn-glycero-3-phos-
phocholine ([14C]PAPC) (50 Ci/mol) is from NEN,
and 1-palmitoyl-2-[1-14C]palmitoyl-sn-glycero-3-phos-
phocholine ([14C]DPPC) (50 Ci/mol) is from Amer-
sham. The source of 1,2-dioleoyl-sn-glycero-3-phos-
phomethanol (DOPM) and the ester formed from Q-
linolenic acid and umbelliferone (GLU) is as de-
scribed [21]. The other non-radioactive lipids are
from Avanti Polar Lipids. 20:4-COCF3 was prepared
as described [17,18]. 20:4-PO(OMe)F is from Bio-
Mol. 7,7-Dimethyl-5,8-eicosadienoic acid (7,7-Me2-
5,8-20:2) is from Oxford Biomedical Research. Silica
gel-60 (230^400 mesh) is from Merck. Recombinant
cPLA2 was puri¢ed as described [22] to near homo-
geneity (V80% by gel electrophoresis, speci¢c activ-
ity of 0.033 Wmol/min/mg using the previously de-
scribed assay [22]). iPLA2 was puri¢ed V75 000-
fold from murine P388D1 cells through the Mono
Q step as described elsewhere [23] and had a speci¢c
activity of 1.6 Wmol/mg/min using the described assay
[24].
Fig. 1. Structures of cPLA2 and iPLA2 inhibitor 20:4-COCF3 and inactivator 20:4-PO(OMe)F.
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2.2. Synthesis of tri£uoromethyl ketones
All tri£uoromethyl ketones were synthesized from
the appropriate acyl chlorides as described previously
[17]. All fatty acyl chlorides were obtained from Nu-
Chek Prep except for the acyl chloride derived from
7,7-Me2-5,8-20:2, which was prepared from the fatty
acid with the standard procedure using oxalyl chlo-
ride in benzene. Ph(CH2)3-COCl and Ph(CH2)4-
COCl were prepared by oxidizing the appropriate
alcohols (Aldrich) with Jones’ reagent followed by
reaction of the carboxylic acids with 1 equivalent
of PCl5 in CH2Cl2 overnight at room temperature.
All compounds were puri¢ed to homogeneity by
£ash chromatography on silica. Compounds were
judged to be pure by thin layer chromatography on
silica with 10% ether in petroleum ether (Rf values
V0.2) and by HPLC on a C18 reverse phase column
using a gradient from 0^100% acetonitrile in water
(UV detection at 210 nm).
2.3. Synthesis of methyl alkyl £uorophosphonates
Ph(CH2)4-PO(OMe)F was prepared as follows. To
2 g of Ph(CH2)4OH (Aldrich) in 2 ml of CH2Cl2 was
added dropwise 1.2 equivalents of PBr3 with stirring,
and the reaction was left at room temperature for an
additional 30 min. Ether was added to the mixture
and the solution was washed with ice-cold brine. The
bromide was puri¢ed by £ash chromatography on
silica with ethyl acetate/petroleum ether.
To prepare Ph(CH2)4-PO(OMe)2, 200 mg of NaH
(60% dispersion in oil) was added to 0.95 ml of dry
DMF. After hydrogen evolution ceased, the £ask
was placed under Ar, cooled in an ice-water bath,
and 0.42 ml of dimethyl phosphite was added drop-
wise by syringe with stirring. The reaction was stirred
for an additional 30 min at room temperature. The
mixture was cooled on ice, and 1.1 equivalents of
Ph(CH2)4Br were added dropwise. The reaction
was stirred overnight at room temperature. Solvent
was removed with a Speed-Vac (Savant Instruments),
and the residue was dissolved in ether, and water was
added. The ether layer was removed and combined
with three additional ether extracts of the water
layer. The solution was dried over anhydrous
MgSO4, ¢ltered, and concentrated to dryness in va-
cuo. Thin layer chromatography on a silica plate
with ethyl acetate showed a single spot at Rf = 0.3:
1H-NMR (CDCl3, TMS) 1.58^1.92, m, 4H; 2.62, t,
2H; 3.71, d, 6H; 7.20, m, 5H.
The dimethylphosphonate (5 mmol) was dissolved
in 11.6 ml MeOH containing 1.35 g NaOH, and the
mixture was re£uxed at 98‡C for 2 h. Water was
added, and the mixture was extracted three times
with ether, and the organic phases were discarded.
The water layer was brought to pH 1, and the prod-
uct was extracted with three portions of ether. The
organic phases were combined, dried over anhydrous
MgSO4, ¢ltered, and concentrated to dryness in va-
cuo: 1H-NMR (CDCl3, TMS) 1.56^1.90, m, 4H;
2.62, t, 2H; 3.71, d, 3H; 7.21, m, 5H.
Ph(CH2)4-PO(OMe)OH (3.3 mmol) was £uori-
nated in 6 ml dry CH2Cl2 (distilled over CaH2 under
Ar) by dropwise addition of Et2NSF3 (DAST,
5 mmol, Aldrich) with stirring at room temperature
under Ar for 30 min. Thin layer chromatography on
silica with ethyl acetate/petroleum ether (1/1) showed
a major spot at Rf = 0.6. The product was puri¢ed by
£ash chromatography on silica with 25% ethyl
acetate in petroleum ether: 1H-NMR (CDCl3,
TMS) 1.49^2.02, m, 4H; 2.61, t, 2H; 3.82, d, 3H;
7.19, m, 5H. The product was judged to be pure
by thin layer chromatography and by HPLC on
a C18 reverse phase column using a gradient of
0^100% acetonitrile in water (UV detection at 210
nm).
16:0-PO(OMe)F was made as described above
starting with hexadecyl bromide (Aldrich). The ¢nal
product was pure as judged by thin layer chromatog-
raphy on silica (Rf = 0.85, ethyl acetate/petroleum
ether, 1/1) and by HPLC (as described above): 1H-
NMR (CDCl3, TMS) 0.89, t, 3H; 1.28, s, 24H; 1.55^
1.80, m, 2H; 1.80-2.02, m, 2H; 3.88, d, 3H.
The short-chain methyl £uorophosphonate
CH2xCH(CH2)5PO(OMe)F was prepared by react-
ing 1-bromo-5-hexene (prepared by treating 5-hexe-
nol with PBr3) with dimethyl phosphite followed by
saponi¢cation and £uorination as described above.
The product was puri¢ed by £ash chromatography
using hexane:ether (1:1). Final puri¢cation was car-
ried out by preparative thin layer chromatography
using chloroform, the product structure was con-
¢rmed by 1H-NMR.
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2.4. cPLA2 vesicle assay
cPLA2 was assayed with DOPM vesicles contain-
ing GLU exactly as described previously using 100
WM DOPM extruded vesicles containing 0.02 mol
fraction GLU in 50 mM Tris, 150 mM NaCl, 0.3
mM CaCl2, 0.2 mM EGTA, 30% glycerol (v/v), pH
8.0 [21]. Inhibitors were added from stock solutions
in DMSO. The concentration of organic solvent in
the assay never exceeded 0.5%. The rate of GLU
hydrolysis in the absence of cPLA2 was measured
in all assays, but in all cases its value was negligible
compared to the enzymatic rate, and thus no correc-
tion was needed. Control reactions were carried out
without inhibitor (DMSO only). Because some of the
inhibitors exhibited slow binding behavior, the reac-
tion progress was monitored until a constant, steady-
state rate was obtained (typically several min). The
concentration of each inhibitor (mol fraction in the
interface) required to reduce the velocity 2-fold,
XI(50), was determined from dose-response curves
with at least six data points.
Prior to use in these and other inhibition studies,
all inhibitors were routinely checked for purity by
thin layer chromatography on silica as described. In-
hibitors containing unsaturated hydrocarbon chains
are susceptible to air oxidation, and stock solutions
were stored at 320‡C under Ar.
2.5. cPLA2 mixed-micelle assay
Assays were performed in bu¡er composed of 80
mM HEPES (pH 7.4), 150 mM NaCl, 10 mM CaCl2,
1 mg/ml fatty acid-free bovine serum albumin (BSA),
and 1 mM dithiothreitol. The mixed-micelle assay
also contained 1 mM [14C]PAPC (120 000 cpm),
2 mM Triton X-100 and 30% (v/v) glycerol in a ¢nal
volume of 200 Wl. The substrate solution was pre-
pared in a solution containing all assay components
except enzyme and inhibitor and at a 1.33-fold high-
er concentration than that desired in the ¢nal assay
mixture. This solution was probe sonicated on ice for
6 min (0.5 s on and 0.5 s o¡ cycles). An aliquot of
this substrate solution (150 Wl) was added to 10 Wl of
inhibitor in DMSO in a siliconized tube. This mix-
ture was vortexed and then warmed to 40‡C for 15
min. cPLA2 (0.75 Wg) in 40 Wl of assay bu¡er was
then added to initiate the reaction. Assays were kept
at 40‡C for 40 min. The reaction was quenched and
worked-up using a modi¢ed Dole protocol as de-
scribed previously [25]. The amount of radiolabeled
arachidonic acid product was quanti¢ed by scintilla-
tion counting.
cPLA2 activity was also measured with varying
times of preincubation of inhibitor with enzyme. In
these experiments, 7.5 Wg of cPLA2 was preincubated
at 21‡C with 40 Wl of a bu¡er containing all assay
components except substrate to which 4 Wl of inhib-
itor in DMSO was added. At the desired times, 4 Wl
of this mixture was added to 196 Wl of substrate in
assay bu¡er (see above) at 40‡C. The incubation and
product analysis was as described above.
Control experiments were carried out using neat
DMSO in place of inhibitor/DMSO. Blank reactions
were carried out in the absence of enzyme, and the
background hydrolysis was subtracted from the data
obtained with enzyme. XI(50) values were determined
by ¢tting the data to a dose-response curve derived
from experiments with at least six di¡erent concen-
trations of inhibitor. Inhibitor concentrations are ex-
pressed as mol fraction inhibitor in the mixed micelle
(mol of phospholipid+mol of Triton X-100).
2.6. iPLA2 mixed-micelle assay
Assays of the iPLA2 were performed with mixed-
micelles composed of 100 WM [14C]DPPC (200 000
cpm), 400 WM Triton X-100 in 100 mM HEPES
(pH 7.5), 5 mM EDTA, and 1 mM ATP in a ¢nal
volume of 500 Wl. The substrate solution was pre-
pared as described previously [23]. An aliquot of
this substrate solution (445 Wl) was added to 5 Wl of
DMSO containing inhibitor in a siliconized tube. This
mixture was agitated brie£y on a vortexer and then
warmed to 40‡C for 15 min. Assays were initiated by
the addition of 50 Wl of iPLA2 in mono Q bu¡er [23].
The mixture was incubated for 30 min at 40‡C. The
reaction was quenched and analyzed for product as
described for the cPLA2 mixed-micelle assay.
iPLA2 activity was also measured after various
times of preincubation of enzyme with inhibitor. In
these experiments, 45 Wl of iPLA2 was preincubated
at 40‡C with 5 Wl of DMSO containing inhibitor.
After the desired times, 450 Wl of substrate solution,
prewarmed to 40‡C, was added to initiate the reac-
tion. The remainder of the assay is as described
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above. Blanks and controls were conduced as in the
cPLA2 assay.
2.7. cPLA2 natural membrane assay
Human U937 cells were grown in suspension
under standard conditions and harvested by centrif-
ugation. The resulting cell pellet was resuspended in
10 ml per 109 cells of ice-cold 20 mM HEPES, pH
7.4, 150 mM NaCl, 1 mM EDTA, 0.5 mM phenyl-
methylsulfonyl £uoride. The resuspended cells were
lysed by 3 cycles of nitrogen cavitation (700 psi,
4‡C). The resulting lysate was centrifuged at
50 000Ug for 60 min at 4‡C, and the supernatant
was discarded. The membrane pellet was resus-
pended in lysis bu¡er without EDTA but containing
1 mg/ml fatty acid-free BSA and then centrifuged
again. The resulting membrane pellet was suspended
in 10 ml of 20 mM HEPES, pH 7.4, 150 mM NaCl
bu¡er per 109 cells.
Inhibitor and U937 cell membranes (equivalent to
1U106 U937 cells, V400 WM phospholipid based on
phosphate analysis) were mixed in 120 Wl of 20 mM
HEPES, pH 7.4, 150 mM NaCl, 3.5 mM CaCl2 for
5 min at 37‡C. The reaction was initiated by the
addition 1 Wg cPLA2 in 100 Wl 20 mM HEPES, pH
7.4, 150 mM NaCl, 1.8 mM EGTA (prewarmed to
37‡C). After a 10 min incubation at 37‡C, the reac-
tion was quenched with 200 Wl of cold methanol con-
taining 100 Wg/Wl of 5,6,8,9,1,12,14,15-[2H]20:4. The
mixture was extracted with chloroform, the organic
layer was concentrated to dryness with a stream of
N2, and the fatty acids were derivatized in methylene
chloride containing 10% (v/v) penta£uorobenzyl bro-
mide and 10% (v/v) diisopropylamine for 20 min at
room temperature. The solvent was removed in va-
cuo, the residue was dissolved in 200 Wl decane and
analyzed by gas chromatography/mass spectrometry
[3]. Liberated arachidonate was quanti¢ed by moni-
toring the ratio of 303/311 m/z ratio.
3. Results and discussion
3.1. Inhibition studies with fatty alkyl tri£uoromethyl
ketones
Virtually any fatty acid can be converted into its
tri£uoromethyl ketone analog by conversion to the
acid chloride followed by reaction with tri£uoroacet-
ic anhydride in pyridine [26]. The 13 tri£uoromethyl
ketones prepared in this study are listed in Table 1.
All compounds contain a long-chain fatty alkyl
group except for Ph(CH2)3-COCF3 and Ph(CH2)4-
COCF3. The latter two compounds are analogs of
the carboxyl end of 20:4-COCF3 in that they contain
an aromatic ring near the position occupied by the 5-
double bond of 20:4. We prepared 22:6-COCF3 with
the thought that it would be a poor cPLA2 inhibitor
but retain good activity toward iPLA2. This is based
on the fact that phospholipids containing an sn-2
22:6 chain are poor cPLA2 substrates [27,28]. Like-
wise, 11,14-20:2-COCF3 and 11,14,17-20:3-COCF3
were prepared because substrate speci¢city studies
of cPLA2 showed that the 5-double bond is the
most important of the four in 20:4 for recognition
by this enzyme [29]. Fatty acid analogs containing
trans double bonds, 9t-18:1-COCF3 and 9t,12t-
18:2-COCF3, were prepared to explore the conse-
quence of having altered double bonds stereochem-
istry, and ¢nally 7,7-Me2-5,8-20:2-COCF3 was pre-
pared because it has a branched fatty alkyl chain.
All inhibitors were tested using assays containing
phospholipid vesicles, phospholipid-detergent mixed
micelles, and crude membranes derived from U937
cells. For vesicle assays, the £uorimetric substrate,
GLU, present at low mol fraction in vesicles of the
anionic phospholipid DOPM was used. This assay
has been well characterized, and cPLA2 binds very
tightly to these anionic vesicles [21]. Anionic phos-
pholipids containing two saturated fatty acyl chains
were avoided since cPLA2 rapidly inactivates on
vesicles composed of such lipids [22]. It has previ-
ously been shown that cPLA2 hydrolyzes arachidon-
yl-containing phospholipids when dispersed in Triton
X-100 micelles [30,31], and this assay was also used.
Finally, a natural membrane assay was used to
mimic inhibition in a natural cell.
For all assays, inhibitors were tested at low mole
fraction, which helps to insure that inhibition is the
result of direct binding of inhibitor to the enzyme
rather than due to desorption of enzyme from the
interface into the aqueous phase. The latter is a seri-
ous concern with PLA2 inhibitors [6,9]. The tri£uoro-
methyl ketones exhibit slow binding behavior with
cPLA2 but not with iPLA2 [17,18,24]. Thus for
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Table 1
XI(50) values for tri£uoromethyl ketones
R-COCF3 cPLA2 DOPM/GLU cPLA2 mixed-micelle cPLA2 mixed-micelle 4 h pre-
incubation
cPLA2 natural membrane iPLA2 mixed-micelle
20:4 0.0050 þ 0.001a (1.00)b 0.036 þ 0.006c (1.00) 0.0053 þ 0.0006d (1.00) 0.05 þ 0.02 (1.00) 0.031 þ 0.006e (1.00)
11,14,17-20:3 0.0085 þ 0.002 (0.59) 0.020 þ 0.002 (1.80) 0.0073 þ 0.007 (0.73) 0.10 þ 0.03 (0.50) 0.0079 þ 0.0008 (3.92)
11,14-20:2 0.017 þ 0.002 (0.29) 0.056 þ 0.009 (0.64) 0.0040 þ 0.0007 (1.33) 0.09 þ 0.02 (0.56) 0.055 þ 0.007 (0.56)
7,7-Me2-5,8-20:2 0.20 þ 0.03 (0.025) 0.022 þ 0.005 (1.64) not determined s 0.5 (0.0) 0.091 þ 0.06 (0.34)
22:6 0.035 þ 0.005 (0.14) 0.047 þ 0.01 (0.77) 0.050 þ 0.02 (0.11) not determined 0.029 þ 0.002 (1.07)
6,9,12-18:3 0.0085 þ 0.001 (0.59) 0.040 þ 0.01 (0.90) 0.012 þ 0.007 (0.44) 0.18 þ 0.04 (0.28) 0.055 þ 0.009 (0.56)
9,12,15-18:3 0.010 þ 0.002 (0.50) 0.029 þ 0.01 (1.80) 0.018 þ 0.01 (0.29) 0.05 þ 0.02 (1.0) 0.0091 þ 0.0009 (3.41)
9t,12t-18:2 0.0065 þ 0.001 (0.77) 0.016 þ 0.009 (2.25) 0.0050 þ 0.002 (1.06) not determined 0.025 þ 0.005 (1.24)
9t-18:1 0.027 þ 0.002 (0.18) 0.013 þ 0.005 (2.77) 0.013 þ 0.006 (0.41) 0.27 þ 0.04 (0.18) 0.057 þ 0.002 (0.54)
16:1 0.0083 þ 0.001 (0.60) 0.010 þ 0.003 (3.60) 0.0046 þ 0.001 (1.15) 0.07 þ 0.02 (0.67) 0.0029 þ 0.0002 (10.7)
16:0 0.025 þ 0.002 (0.20) 0.022 þ 0.006c (1.64) 0.019 þ 0.003 (0.28) 0.20 þ 0.03 (0.25) 0.0085 þ 0.0006f
(3.65)
Ph(CH2)3 0.17 þ 0.02(0.03) 0.12 þ 0.06 (0.30) 0.20 þ 0.1 (0.026) s 0.5 (0.0) 0.28 þ 0.06 (0.11)
Ph(CH2)4 0.038 þ 0.001 (0.13) 0.040 þ 0.01 (0.90) 0.048 þ 0.002 (0.11) s 0.5 (0.0) 0.0043 þ 0.0002 (7.21)
aBayburt et al. reported an XI(50) of 0.01 [21].
bNumbers in parentheses are the potencies of the inhibitors relative to 20:4-COCF3 (XI(50) for AACOCF3 divided by XI(50) for RCOCF3).
cConde-Frieboese et al. reported XI(50)s of 0.016 and 0.015 for 20:4 and 16:0, respectively [25].
dConde-Frieboese et al. reported XI(50) of 0.005 [25].
eAckermann et al. reported an XI(50) of 0.028 [18].
f Conde-Frieboese et al. reported XI(50) of 0.006 [25].
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cPLA2 assays, it is important to record the enzymatic
velocity after equilibrium between enzyme and inhib-
itor is reached. The DOPM/GLU assay gives a real-
time progress curve, and the velocity was monitored
until a constant steady-state velocity was obtained
(typically several min). The assay with [14C]PAPC/
Triton X-100 mixed micelles is a ¢xed-time point
assay, and thus enzyme was preincubated with mi-
celles containing inhibitor for 4 h prior to the addi-
tion of substrate-containing micelles to initiate the
reaction. For comparison purposes, inhibition was
also measured without preincubation, i.e. by addition
of cPLA2 to micelles preloaded with substrate and
inhibitor.
Table 1 lists the mole fraction of each inhibitor
required to produce 50% inhibition, designated
XI(50). Inhibitors of lipolytic enzymes are best re-
ported in terms of mole fraction of inhibitor in the
membrane [10,32]. Table 1 also gives the potency of
each tri£uoromethyl ketone relative to that of 20:4-
COCF3 [XI(50) for 20:4-COCF3/XI(50) for
RCOCF3] for each assay. For any single assay, the
ratio of XI(50)s for two inhibitors is equal to the
ratio of the interfacial enzyme-inhibitor dissociation
equilibrium constants, KI*, and thus the relative po-
tencies are identical to the relative 1/KI* values. It is
di⁄cult to compare two XI(50) values obtained for
one inhibitor measured with two di¡erent assays.
This is because the degree of inhibition in the pres-
ence of any particular mole fraction of inhibitor in
the interface is a function not only of KI* but also of
the interfacial Michaelis constant for substrate, KM*,
and the degree to which the non-substrate lipid that
forms most of the interface (DOPM or Triton X-100
or natural membrane lipids) competes with the inhib-
itor for binding to the active site of cPLA2 (non-
neutral diluent e¡ect [33]). However, if relative values
of XI(50) for a series of inhibitors in one assay are
the same as those in the other assay, then the relative
values of KI* in the two assays will be the same. It
should also be noted that the relative potencies for
the inhibitors measured with the mixed-micelle assay
with and without preincubation are di¡erent (Table
1), which indicates that the inhibitors bind to cPLA2
with di¡erent rates. Thus it is best to compare the
XI(50)s obtained with the vesicle assay (measured
after a constant steady-state enzymatic velocity was
obtained) to those obtained with the preincubation
mixed-micelle assay since equilibration between en-
zyme and inhibitor has occurred under these condi-
tions.
Fig. 2A,B gives a graphical representation of the
relative potencies obtained with the vesicle, preincu-
bation mixed-micelle, and natural membrane assays.
There is good agreement between the relative poten-
cies of the tri£uoromethyl ketones in all three assays,
although there are a few exceptions. 11,14^20:2-
COCF3 and 16:1-COCF3 are, respectively, 4.5-fold
and 1.9-fold more potent in the mixed-micelle assay
compared to the vesicle assay, and 9,12,15-COCF3 is
2-fold more potent in the natural membrane assay
versus the vesicle assay. Overall, the data suggest
that for most tri£uoromethyl ketones, their relative
KI* values are independent of the lipid matrix that
forms the interface (DOPM versus Triton X-100 ver-
sus U937-derived crude membranes). Based on the
likelihood that the free energy of inhibitor bound
to cPLA2 is dominated by enzyme-inhibitor interac-
tions and the free energy of inhibitor in the interface
is dominated by the hydrophobic e¡ect, one may
expect relative values of KI* in the di¡erent assays
to be similar. The data also argue that both the
vesicle and mixed-micelle assays give an accurate rel-
ative impression of how well a particular inhibitor
will work in a natural membrane.
For cPLA2, the XI(50) values for the inhibitors in
both the vesicle and mixed-micelle assay (with pre-
incubation) are within a factor of 2 of each other
except as noted above. In contrast, the XI(50) values
in the natural membrane assay are typically 10-fold
higher. The reason for this is not known, but it is
likely due to the fact that the concentration of sn-2-
arachidonyl phospholipid substrates for cPLA2 in
natural membranes is much higher than the concen-
tration of substrate present in DOPM vesicle and
Triton X-100 micelles.
The same series of tri£uoromethyl ketones was
tested for inhibition of iPLA2 using a Triton X-100
mixed-micelle assay, and the data are listed in Table
1. There is virtually no correlation between the rela-
tive potencies of the series of tri£uoromethyl ketones
as inhibitors of cPLA2 versus iPLA2. For example,
16:1-COCF3 and Ph(CH2)4-COCF3 are, respectively,
10.7-fold and 7.2-fold more potent than 20:4-COCF3
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against iPLA2, whereas they are 1.7- and 7.7-fold,
respectively, less potent than 20:4-COCF3 against
cPLA2.
Among the cPLA2 inhibitors, 20:4-COCF3 is the
best inhibitor of the series. 22:6-COCF3 is 7-fold less
potent than 20:4-COCF3 in vesicles, which is consis-
tent with the fact that cPLA2 greatly prefers phos-
pholipid substrates with an sn-2-20:4 chain over
Fig. 2. In vitro inhibition of cPLA2 by tri£uoromethyl ketones measured with three di¡erent assays. (A) The abscissa gives the relative
potency of the indicated tri£uoromethyl ketones as an inhibitor of cPLA2 (XI(50) for 20:4-COCF3 divided by XI(50) for test com-
pound) using the vesicle assay, and the ordinate gives the relative potency for the same set of compounds measured with the mixed-
micelle assay (R group of R-COCF3 given next to each data point). (B) Same as (A) but relative potency in the natural membrane as-
say is compared to that measured in the vesicle assay.
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those with an sn-2-22:6 chain (as noted above). Ap-
parently, replacing the 5-double bond of 20:4-
COCF3 with an aromatic ring [Ph(CH2)3-COCF3
and Ph(CH2)4COCF3] leads to a poor ¢t in the ac-
tive site of cPLA2. Loss of the 5-double bond (11,14-
20:2-COCF3 and 11,14,17-COCF3) results in a mod-
est reduction in potency. Alkyl chain branching (7,7-
Me2-5,8-20:2) is not tolerated well by cPLA2. Fi-
nally, shortening the chain length with removal of
double bonds (16:1-COCF3 and 16:0-COCF3) leads
to only a modest reduction in potency [18]. This is in
marked contrast to previous results showing that
20:0-COCF3 is much less potent as a cPLA2 inhib-
itor compared to 20:4-COCF3 [17].
iPLA2 displays a very di¡erent pattern. It does not
discriminate between 20:4-COCF3 and 22:6-COCF3,
and it prefers 16:1-COCF3 and 16:0-COCF3 over
20:4-COCF3. An aromatic ring enhances inhibition
when linked to the carbonyl group by a four carbon
chain, but moving the ring closer by 1 methylene
drastically reduces inhibition.
Fig. 3. Inactivation of cPLA2 by 20:4-PO(OMe)F. Reaction progress curve for the hydrolysis of 0.02 mol fraction GLU in 100 mM
DOPM vesicles in assay bu¡er (see Section 2) by 0.1 Wg cPLA2. 20:4-PO(OMe)F was added at a concentration of 0.005 mol fraction
at the time indicated by the arrow.
Table 2
Inactivation of cPLA2 and iPLA2 by fatty alkyl methyl £uorophosphonates
Inactivator cPLA2 ki*/KI* (mol fraction)31 s31 cPLA2 ki/KI M31 s31 iPLA2 ki/KI M31 s31
20:4-PO(OMe)F 2.30 þ 0.03a 4.8 þ 0.5b 2 300 þ 800b
16:0-PO(OMe)F 0.57 þ 0.02 3.7 þ 0.3 13 300 þ 3000
Ph(CH2)4PO(OMe)F 0.12 þ 0.02 1.15 þ 0.3 10 800 þ 3000
CH2xCH(CH2)5PO(OMe)F 0.15 þ 0.04 2.8 þ 0.7 not determined
aMeasured from the rate of inactivation observed in real time with the DOPM/GLU assay.
bMeasured by pre-incubating enzyme with inactivator in the aqueous phase and adding mixed-micelle substrate at various times to
measure the fraction of remaining active enzyme.
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3.2. Inhibition studies with methyl fatty
alkyl£uorophosphonates
Based on the above results with tri£uoromethyl
ketones, we prepared two £uoromethyl phospho-
nates, 16:0-PO(OMe)F and Ph(CH2)4-PO(OMe)F,
that were anticipated to distinguish between cPLA2
and iPLA2. These compounds result in a slow loss of
cPLA2 activity (DOPM/GLU assay), presumably
due to enzyme inactivation as is the case for 20:4-
PO(OMe)F [19]. Fig. 3 shows a typical cPLA2 reac-
tion progress curve before and after the addition of
20:4-PO(OMe)F. For these inactivators, it is best to
report the observed ¢rst-order rate constant for in-
activation divided by the mole fraction of inactivator
in the interface. Such a quantity is proportional to
ki*/KI*, where KI* is the mole fraction of inactivator
that causes half of the interface-bound enzyme, E*,
to be in the reversibly inhibited complex E*cI*, and
ki* is the rate constant for conversion of E*cI to the
covalent E*-I complex. Values of ki*/KI* relative to
that for 20:4-PO(OMe)F are listed in Table 2. Based
on these measurements, the order of potency is 20:4-
PO(OMe)Fs16:0-PO(OMe)FsPh(CH2)4-PO(OMe)-
F, a trend that is consistent with the analogous series
of tri£uoromethyl ketones.
We also studied the rate of cPLA2 inactivation
when enzyme and inactivator were incubated for var-
ious times in the aqueous phase, and the fraction
remaining active enzyme was measured by addition
of substrate (in the form of mixed micelles). The
observed ¢rst-order rate constant for loss of enzy-
matic activity divided by the bulk concentration of
inactivator in the aqueous phase gives ki/KI, where
KI is the equilibrium constant for the reaction EcI
CE+I, and ki is the rate constant for EcI E-I (all in
the aqueous phase). Values of ki/KI are listed in Ta-
ble 2. Although ki/KI cannot be compared to ki*/KI*
(they have di¡erent units), it is clear that cPLA2
bound to the interface is much more sensitive to in-
activation than enzyme in the aqueous phase. For
example, for cPLA2 bound to DOPM vesicles con-
taining 0.005 mol fraction 20:4-PO(OMe)F, inactiva-
tion occurs with a half-time of 60 s. In this experi-
ment, the mole of inactivator divided by the total
reaction volume corresponds to 0.5 WM 20:4-PO(O-
Me)F in the reaction. In the absence of an interface,
incubation of cPLA2 with 0.5 WM 20:4-PO(OMe)F
in the aqueous phase would lead to inactivation with
a half-time of 3U105 s (calculated from the ki/KI
value in Table 2). This result is in marked contrast
to inactivation of secreted PLA2s where it has been
shown that the half-times for inactivation by phena-
cylbromides of enzyme in the aqueous phase and
bound to an interface of a neutral diluent are similar
[33]. Based on theoretical arguments which have been
experimentally veri¢ed, this dramatic increase in ap-
parent inactivation potency when cPLA2 is preincu-
bated with methyl £uorophosphonate in aqueous sol-
ution versus presented with the inactivator bound to
an interface may not be due to local concentration
e¡ects (i.e. enzyme sees a high local concentration of
inactivator when both are bound to vesicles versus
dispersed in the aqueous phase) [33]. Rather the re-
sults argue that the interface-bound enzyme is in-
trinsically more susceptible to inactivation.
We also prepared short-chain methyl £uoro-
phosphonate CH2xCH(CH2)5PO(OMe)F and tested
it as an inactivator of cPLA2 using the DOPM/GLU
assay (Table 2). In the aqueous phase in the absence
of an interface, cPLA2 is inactivated by
CH2xCH(CH2)5PO(OMe)F with a second-order
rate constant of 2.8 þ 0.7 M31 s31 (half-time for in-
activation of 82 min with 50 WM inactivator). The
half-time for cPLA2 inactivation by 50 WM
CH2xCH(CH2)5PO(OMe)F in the presence of
1000 WM DOPM vesicles (to ensure that all of the
inactivator is partitioned into the interface) contain-
ing 0.02 mol fraction GLU decreased to 1.5 min
corresponding to a ki*/KI* of 0.15 (mole fraction)31
s31. These results show that CH2xCH(CH2)5-
PO(OMe)F behaves similarly to Ph(CH2)4PO-
(OMe)F as a cPLA2 inactivator in the presence and
absence of vesicles. They also show that the methyl
£uorophosphonate with a short straight-chain alkyl
group is a less e⁄cient cPLA2 inactivator than are
the long-chain compounds (Table 2).
Inactivation of iPLA2 was studied by preincubat-
ing enzyme in the aqueous phase with inactivator at
40‡C followed by addition of mixed-micelle substrate
to measure the fraction of remaining enzymatic ac-
tivity (data in Table 2). Ph(CH2)4-PO(OMe)F and
16:0-PO(OMe)F show similar potencies, and 20:4-
PO(OMe)F is considerably less potent. Note that
nanomolar amounts of methyl £uorophosphonates
are su⁄cient to inactivate most of the iPLA2 during
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preincubation in the aqueous phase for 20 min. In
marked contrast, micromolar amounts of these com-
pounds are required to inactivate most of the cPLA2
in preincubations lasting 200 min (Table 2).
Fig. 4 shows the results of inactivation of cPLA2
by fatty alkyl methyl £uorophosphonates present in
the natural membrane assay. In this assay, various
mole fractions of 20:4-PO(OMe)F and Ph(CH2)4-
PO(OMe)F were added to natural membranes,
cPLA2 was added, and the amount of arachidonate
release was quanti¢ed after a ¢xed incubation time.
It can be seen that 20:4-PO(OMe)F is much more
potent than Ph(CH2)4-PO(OMe)F. The reason for
the approximately 2-fold increase in arachidonate
production in the presence of Ph(CH2)4-PO(OMe)F
is unknown.
Overall, the results show that the in vitro rank
order potency of the fatty alkyl methyl £uoro-
phosphonates as inactivators of cPLA2 and iPLA2
is the same as that seen with the corresponding tri-
£uoromethyl ketones.
4. Conclusions
We have prepared an expanded set of fatty alkyl
tri£uoromethyl ketones and methyl £uorophospho-
nates that distinguish between cPLA2 and iPLA2,
and thus should be useful to study the roles of these
enzymes in cellular processes such as arachidonic
acid release and lipid remodeling. Although the ab-
solute potencies of PLA2 inhibitors measured with
di¡erent assays cannot be easily compared in a
meaningful way, the relative potencies of a series of
inhibitors (and inactivators) measured with vesicle,
detergent-phospholipid mixed-micelle, and natural
membrane assays are similar. Thus, at least for the
inhibitors studied here, the free energy change for the
transfer of inhibitor from the active site of the en-
zyme bound to the interface to the interface is ap-
proximately invariant to the type of interface used.
Such a conclusion was also noted by Jain et al. in
their use of a neutral diluent to measure interfacial
KM values of PLA2s [33]. Still, the problem remains
Fig. 4. Inactivation of cPLA2 by £uoromethyl phosphonates in the natural membrane assay. Assays were carried out as described in
Section 2 with the indicated concentrations of 20:4-PO(OMe)F (b) or Ph(CH2)4-PO(OMe)F (a). Error bars designate the standard de-
viation obtained from duplicate experiments. The mole fraction of inhibitor is calculated based on total membrane phospholipid (de-
termined by phosphate analysis). Inhibition is expressed as a percentage of the arachidonate released in the absence of inhibitor
(309 þ 69 pg/Wl injected). All release values were corrected for the amount of arachidonate released in the absence of added cPLA2
(54 þ 12 pg/Wl injected).
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that many investigators carry out lipolytic enzyme
inhibitor studies with concentrations of inhibitors
comparable to the concentration of substrate used
in the assay. Under such conditions, the mole frac-
tion of inhibitor in the interface may be quite high,
and one has to be concerned that the presence of
inhibitor may cause desorption of the enzyme from
the interface into the aqueous phase [6]. Based on the
results of this study, it may now be said that regard-
less of the type of assay used, vesicle, mixed-micelle,
or natural membrane, true inhibitors of PLA2 can be
discovered as long as the mole fraction of inhibitor in
the interface is keep low (perhaps 6 0.01).
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